Needle biopsy of the kidney in 1 of these patients ... 13 We have found this true of a wide variety of renal diseases — for example, amyloid and Kimmelstiel–Wilson disease.

The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...

To determine the diagnostic accuracy of the results of CSF tests compared to the gold standard PET imaging, the Munich researchers evaluated the data of over 400 patients with suspected Alzheimer's ...

The first drugs against Alzheimer's disease that are intended to slow down the progression of the condition will soon be authorized in Germany. On November 14, 2024, the EMA granted approval for ...

The stock market responded positively to the company's announcement, with its share price leaping more than 28% following the ...

The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...

The disorder most frequently affects the heart, kidneys, gastrointestinal tract, and nervous system. Other common sites of amyloid accumulation include the tongue, skeletal and smooth muscles ...

BridgeBio Pharma Inc. (BBIO) announced that the U.S. Food and Drug Administration approved Attruby or acoramidis, an ...

Ultromics Ltd. received clearance from the U.S. FDA for Echogo Amyloidosis, its artificial intelligence-enhanced software ...

The oral drug, branded as Attruby, was approved to treat adult patients with transthyretin amyloid cardiomyopathy (ATTR-CM), ...